Yun Wu

FDA investigator

Appears on 5 documents from 2020 to 2023, most often at sites in North Carolina. Most often cites production record review (21 CFR 211.192).

5
Documents on file
4.0
Observations per 483
2020
First seen
2023
Most recent

What they cite most

From 20 observations

Activity by year

2020: 2, 2021: 2, 2023: 1

Where

North Carolina 2 · Australia 1 · Singapore 1 · South Korea 1

Is Yun Wu coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 Patheon Biologics Australia Pty LtdOct 17, 2023 · Woolloongabba, Australia
483 Samsung Biologics Co., Ltd. 300 Songdo bio-daero, Yeonsu-guAug 24, 2021 · Incheon, South Korea
483 Fujifilm Diosynth Biotechnologies USA, Inc.Apr 21, 2021 · Morrisville, North Carolina
483 Patheon Manufacturing Services LLCAug 14, 2020 · Greenville, North Carolina
483 Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.Feb 15, 2020 · Singapore, Singapore

About this profile

What does Yun Wu inspect?

Yun Wu appears on 5 documents on file covering 5 sites, most often in North Carolina.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.100 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Yun Wu is dated Oct 17, 2023.